Indotecan (LMP400) is primarily investigated for its potential in cancer treatment, particularly as a topoisomerase I inhibitor. It works by interfering with the enzyme topoisomerase I, which is crucial for DNA replication and repair in cancer cells. By inhibiting this enzyme, Indotecan induces DNA damage, leading to the death of cancer cells. This mechanism makes it a promising candidate for treating various types of cancers, including solid tumors and hematologic malignancies. Clinical trials are ongoing to evaluate its efficacy, safety, and optimal dosing regimens, with a focus on its ability to overcome resistance to other topoisomerase inhibitors. Additionally, research is exploring its use in combination therapies to enhance its anticancer effects and reduce the likelihood of drug resistance.